US tariffs likely to disrupt drug development costs and prices, says GlobalData
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the pharmaceutical supply chain.
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the pharmaceutical supply chain.
What's Your Reaction?
